A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Latest Information Update: 31 May 2023
At a glance
- Drugs Cinrebafusp alfa (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary) ; Tucatinib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Pieris Pharmaceuticals
- 19 Apr 2023 Results (As of the cut-off date 19-Dec-2022) assessing the efficacy and safety of combination of cinrebafusp alfa with ramucirumab and paclitaxel in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma, presented at the 114th Annual Meeting of the American Association for Cancer Research.
- 19 Jan 2023 This trial has been discontinued in Spain according to European Clinical Trials Database record.
- 07 Sep 2022 Status changed from recruiting to active, no longer recruiting.